Migraines Recent News
FDA Gives Nod To First Oral CGRP Receptor To Prevent Migraine From AbbVie
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study
Biohaven's Nurtec Wins FDA Approval As First Med to Prevent and Treat Migraine Attacks
FDA Accepts AbbVie's Atogepant US Review Application For Migraine
Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant
Satsuma Pharma Shares Rise After Raising $80M Via Private Placement, Plans New Pivotal Study For Migraine
Teva's Preventive Migraine Treatment Approved By FDA
Cramer: Small-Cap Biotechs Are Reserved For Speculative Investors
Alder Biopharma Surged 60% Following Phase 2 Results